Revenue

Varvara Development Group raises C$15M to fund its cyanide-free gold mine in Romania, as major shareholder Eldorado Gold increases its stake to 19.9%.

A major orthopedic group serving the D.C. metro area reveals a data breach, potentially exposing Social Security numbers and sensitive medical histories.

The global bakery's arrival at Metro Centre signals a new era for the area's dining scene and a major win for developer David S. Brown's strategic vision.

New preclinical data shows SK Life Science Labs' protein degraders effectively target key drivers in prostate cancer, myeloma, and other hard-to-treat tumors.

A $2.5M gift honors a legacy and empowers a top scientist to develop imaging tech that could revolutionize how we diagnose and treat blindness.

New data reveals a novel cancer drug shrinks brain metastases in over half of small cell lung cancer patients, offering hope where options are scarce.

With $10M in new funding, Creao AI is building a 'closed-loop' system where AI builds and runs its own tools, promising one person the power of a team.

A new platform watches individual tumor cells to link behavior with biology, offering a powerful tool against treatment resistance in cancers like glioblastoma.

Premier agency VIPs Entertainment is changing how elite events are staffed, launching a new digital platform to streamline booking high-end bands and DJs.

Hainan's 2026 consumer expo showcases flying cars and global brands, all powered by its new, ambitious free trade port policies that are reshaping trade.

A $300M tugboat deal pushes Woodside's investment in Louisiana past $1 billion, boosting the state's maritime industry and its role in global energy.

Aviation Capital Group seeks a new financial chief as Craig Segor steps down after a successful four-year tenure, leaving the firm in a strong position.

Genomic Prediction reappoints its founding CEO, Laurent Tellier, signaling a push for innovation amid ethical debates and questions about its market standing.

Interim trial data shows IPH5201 plus durvalumab yields pathological complete response rates up to 50%, far surpassing current standards for resectable NSCLC.

With new EU eco-design rules looming, Glimpact's funding from Sparkalis signals a major shift toward data-driven sustainability in the agri-food industry.

Presented at AACR 2026, first-in-class antibody IMT-009 shows clinical benefit in tough cancers, potentially paving the way for a new precision therapy.

New data on ATX-295 reveals a potent attack on unstable tumors, guided by an AI biomarker that could change how we select patients for treatment.

Newcomer Capital-FORCE makes a strategic entry into the competitive ETF space by acquiring two established IBD-branded funds from Innovator.

Dynamite Wallet wants to make your face your private key. This leap in usability could ignite mass adoption, but it also raises critical security questions.

Nested Therapeutics' NST-628 reports a 38% response rate in advanced melanoma, offering new hope with a novel, brain-penetrating cancer-fighting agent.